Cyanosis epidemiology and demographics

Revision as of 18:41, 11 March 2018 by Medhat (talk | contribs)
Jump to navigation Jump to search

Cyanosis Microchapters

Home

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Cyanosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Cyanosis epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Cyanosis epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cyanosis epidemiology and demographics

CDC on Cyanosis epidemiology and demographics

Cyanosis epidemiology and demographics in the news

Blogs on Cyanosis epidemiology and demographics

Directions to Hospitals Treating Cyanosis

Risk calculators and risk factors for Cyanosis epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

Epidemiology and Demographics

The reported prevalence of CHD at birth ranges from 6 to 13 per 1000 live births [13-19]. Variation is primarily due to the use of different methods to detect CHD (ie, fetal echocardiography versus postnatal referral to a cardiac center) [17,20].

The most common congenital heart defect is a bicuspid aortic valve (BAV), with a prevalence estimated between 0.5 and 2 percent, but as an isolated lesion it is rarely diagnosed in infancy [21-23]. The next most common defects are ventricular septal defects (VSDs) and secundum atrial septal defects (ASDs, prevalence of 4 and 2 per 1000 live births, respectively) [11,15,24,25]. Tetralogy of Fallot (TOF) (figure 2) is the most common cyanotic CHD (0.5 per 1000 births) [15,26].

CHD is the leading cause of perinatal and infant death from a congenital birth defect, although outcomes have significantly improved with the advancement of corrective or palliative interventions [1,16,27-29].

Critical CHD accounts for approximately 25 percent of all CHD [12]. In infants with critical CHD, the risk of morbidity and mortality increases when there is a delay in diagnosis and timely referral to a tertiary center with expertise in treating these patients [9].

References

Template:WH Template:WS